MAKE AN APPOINTMENT

⚠ COVID-19 INFORMATION: Resources, Vaccine Information

Lurie Children's Research InnovationClinical Studies Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years

Official Title: A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are widely used as part of combination antiretroviral therapy (ART) for infants and children, but NNRTI resistance is increasing, leading to treatment failure. This study will test the safety, tolerability, and dosing levels of etravirine (ETR), a new NNRTI.
NCT01504841
Interventional
Yes

Contact Information:

Margaret Ann Sanders

Research and Education Coordinator

312-227-8275